Search | Clinical Trials Finder

Conditions: QT/QTc Interval in Healthy Volunteers
Interventions: WCK 5222, IV placebo matched to WCK 5222 / Moxifloxacin IV solution, Moxifloxacin 400-mg; Drug
Lead sponsor: Wockhardt; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Insomnia
Interventions: Suvorexant, Placebo; Drug
Lead sponsor: Burdick, Daniel, M.D.; Individual
Eligibility: 30 Years to 80 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Kirkland, Washington

Conditions: Idiopathic Pulmonary Fibrosis (IPF)
Interventions: MNKD-201(Nintedanib DPI), Placebo; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 9
States / cities: Fresno, California • Palm Springs, California • Doral, Florida + 5 more

Conditions: Chronic Kidney Disease, Hepatic Impairment
Interventions: BAY3283142; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: HIV
Interventions: Information, motivation, behavioral skills treatment arm, Information only control arm; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 13 Years to 19 Years
Enrollment: 360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, PF-06882961; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 412 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 42
States / cities: Harbor City, California • Long Beach, California • Los Angeles, California + 33 more

Conditions: Atherosclerotic Cardiovascular Disease, Metabolic Syndrome
Interventions: Health Education, Transcendental Meditation; Behavioral
Lead sponsor: Robert Schneider, MD; Other
Eligibility: 55 Years and older · Female only
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia

Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions: Verinurad, Allopurinol, Placebo for verinurad, Placebo for allopurinol; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 130 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 8
States / cities: Granada Hills, California • Northridge, California • Torrance, California + 5 more

Conditions: Stress, Psychological, Motivation
Interventions: Minocycline, Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 25 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Spinal Cord Injury, Shoulder Pain
Interventions: Shoulder home exercise program; Other
Lead sponsor: Rancho Research Institute, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Downey, California

Conditions: Upper Respiratory Disease, Influenza, Viral Upper Respiratory Infection
Interventions: Immune Defense Protein 50mg Dose, IDP 200mg Dose, Matching Placebo; Dietary Supplement
Lead sponsor: Quantec Ltd; Industry
Eligibility: 60 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Eczema
Interventions: Abrocitinib, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 13
States / cities: Birmingham, Alabama • North Little Rock, Arkansas • San Diego, California + 7 more

Conditions: Duchenne Muscular Dystrophy (DMD)
Interventions: Bocidelpar, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 8 Years to 16 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: Sacramento, California • Kansas City, Kansas • Baltimore, Maryland + 2 more

Conditions: Transgender Women, Substance Abuse, Hiv
Interventions: Adapted SBIRT-T for transgender women; Behavioral
Lead sponsor: University of Central Florida; Other
Eligibility: 18 Years and older · Male only
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Postpartum Depression, Pregnancy Related, Environmental Exposure
Interventions: Nature Coach Intervention; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Acne Vulgaris
Interventions: 1.2% JNJ 10229570-AAA, 2.4% JNJ 10229570-AAA, 3.6% JNJ 10229570-AAA, Vehicle control; Drug · Other
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 431 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 18
States / cities: San Diego, California • Colorado Springs, Colorado • Denver, Colorado + 14 more

Conditions: Hepatic Impairment
Interventions: Lemborexant; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Diabetic Neuropathy, Painful
Interventions: PF-05089771 150 mg, Matched placebo for PF-05089771 150 mg and pregabalin 300 mg, Pregabalin 300 mg, PF-05089771 150 mg + Pregabalin 300 mg; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 32
States / cities: Phoenix, Arizona • Fresno, California • Bradenton, Florida + 24 more

Conditions: Asthma
Interventions: Benralizumab, Placebo; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 20
States / cities: Los Angeles, California • Centennial, Colorado • Denver, Colorado + 16 more

Conditions: Open Abdomen
Interventions: AbCLO (Abdominal Wall Closure) Device; Device
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Los Angeles, California • Boston, Massachusetts

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: BBT-877, Single dose, Placebo group, BBT-877, Multiple doses; Drug
Lead sponsor: Bridge Biotherapeutics, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Obesity, Overweight, Anxiety, Mental Disorders, Body Weight, Eating Behavior, Feeding and Eating Disorders
Interventions: Interpersonal Psychotherapy (IPT), Cognitive Behavioral Theory (CBT); Behavioral
Lead sponsor: The Metis Foundation; Other
Eligibility: 12 Years to 17 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Fort Collins, Colorado • Bethesda, Maryland

Conditions: Adverse Childhood Experiences, Endothelial Dysfunction
Interventions: Nicotinamide Riboside, Placebo; Dietary Supplement
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 30 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Iowa City, Iowa • Madison, Wisconsin

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: Glatiramer Acetate, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 25
States / cities: Cullman, Alabama • Fresno, California • La Jolla, California + 17 more

Search by objective public record fields.

Evaluate the Effect of WCK 5222 on the QT/QTc Interval in Healthy Volunteers

A Pilot Study of Suvorexant for Insomnia in Parkinson Disease

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis

A Study to Learn About How BAY 3283142 Moves Into, Through, and Out of the Body After a Single Dose in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function

Effectiveness and Implementation of Text Messaging to Improve HIV Testing in Adolescents

A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus

Multicenter Trial of Meditation and Health Education for Cardiometabolic Disease in Black Women

Study of Verinurad in Heart Failure With Preserved Ejection Fraction

Brain and Stress Study

Maintenance of Shoulder Health and Function After Spinal Cord Injury

Immune Defense Protein Impact On Respiratory Immune Outcomes

A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema

A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD)

To Reach Unrestricted Services for Transgender Women

Nurtured in Nature

A Study of a New Drug Treatment for Acne

Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects

A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN)

Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy

Assessment of a Non-invasive Device in the Management of Open Abdomen (AbCLO)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 in Healthy Subjects

Addressing Anxiety and Stress for Healthier Eating in Teens

ACEs, SIRT1, and Premature Vascular Aging in Humans

An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)